|Company name||Merck & Co., Inc.|
|Live stock price||[stckqut]MRK[/stckqut]|
|P/E compared to competitors||Fair|
|Confident Investor Rating||Fair|
|Target stock price (TWCA growth scenario)||$75.01|
|Target stock price (averages with growth)||$82.91|
|Target stock price (averages with no growth)||$68.25|
|Target stock price (manual assumptions)||$51.27|
The following company description is from Google Finance: http://www.google.com/finance?q=mrk
Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Effective February 25, 2013, Dashtag, a unit of Merck & Co Inc’s Schering Plough Corp subsidiary acquired 17.95% interest in Fulford (India) Ltd.
Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in this stock as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns. I am leaving the company on my Watch List in the hopes that the metrics will improve a little bit.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.